Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) gapped up before the market opened on Tuesday. The stock had previously closed at $15.36, but opened at $15.89. Ascentage Pharma Group International shares last traded at $15.49, with a volume of 983 shares changing hands.
Analysts Set New Price Targets
Several research firms recently weighed in on AAPG. William Blair started coverage on Ascentage Pharma Group International in a research note on Friday, October 16th. They issued an “outperform” rating on the stock. Citizens Jmp initiated coverage on Ascentage Pharma Group International in a research note on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 price objective for the company. Citigroup assumed coverage on Ascentage Pharma Group International in a research note on Wednesday, October 14th. They set a “buy” rating and a $46.00 price objective for the company. BTIG Research reissued a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Finally, JPMorgan Chase & Co. lowered their price target on Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a research report on Thursday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $43.44.
Get Our Latest Research Report on AAPG
Ascentage Pharma Group International Stock Performance
The firm’s 50 day moving average price is $15.46 and its 200-day moving average price is $19.72. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09.
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last announced its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The company had revenue of $22.24 million for the quarter. On average, research analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 earnings per share for the current year.
Ascentage Pharma Group International Company Profile
Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Featured Stories
- Five stocks we like better than Ascentage Pharma Group International
- The Post-Midterm Rally Clock Is Ticking—and These 3 AI Stocks Stand Out
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
